RJA
PCVX icon

Raymond James & Associates’s Vaxcyte PCVX Stock Holding History

Raymond James & Associates’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$9.28M Buy
81,235
+11,798
+17% +$1.06M 0.01% 1273
2024
Q2 		$5.24M Buy
69,437
+3,105
+5% +$211K ﹤0.01% 1535
2024
Q1 		$4.53M Buy
66,332
+14,779
+29% +$1.02M ﹤0.01% 1659
2023
Q4 		$3.24M Sell
51,553
-2,363
-4% -$123K ﹤0.01% 1809
2023
Q3 		$2.75M Sell
53,916
-693
-1% -$34.2K ﹤0.01% 1828
2023
Q2 		$2.73M Buy
54,609
+47,009
+619% +$2.23M ﹤0.01% 1871
2023
Q1 		$285K Buy
+7,600
New +$322K ﹤0.01% 3267

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James & Associates's PCVX Position: Q3 2024 in Review

Raymond James & Associates increased its Vaxcyte (PCVX) stake by 17% in Q3 2024, buying an estimated $1.06M and bringing the position to 81,235 shares worth $9.28M. The position accounts for 0.01% of the portfolio, ranked #1273.

Raymond James & Associates first reported a position in PCVX in Q1 2023 and has held it in 7 quarters since. 328 funds tracked by Wall St. Rank hold PCVX as of Q3 2024.

  • Raymond James & Associates held 81,235 shares of Vaxcyte worth $9.28M as of Q3 2024.
  • Raymond James & Associates bought 11,798 Vaxcyte shares in Q3 2024, an estimated $1.06M.
  • Vaxcyte made up 0.01% of Raymond James & Associates's portfolio in Q3 2024, its #1273 holding.
  • Raymond James & Associates first reported a position in Vaxcyte in Q1 2023 and has held it in 7 quarters since.
  • 328 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.